Loading live market data…

Vericel Corporation

NASDAQ:VCEL

$46.09 USD

-$1.4 (-2.95%)

Volume
632.95K
Average Volume
648.7K
Market Capitalization
$2.35B
P/E Ratio
107.44
Dividend Yield
0.00%
Price Target
$46.00
Year High
$48.33
Year Low
$28.95
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$5.18
Source Headline
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests

10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin's direct Common Stock holdings, reducing his direct stake from 26,248 to 16,248 shares, though he also has options.

fool.com - 2026-06-27 12:58:26

Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026

BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.

globenewswire.com - 2026-06-09 08:30:00

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

fool.com - 2026-05-30 14:39:34

Vericel Q1 Earnings Call Highlights

Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.

marketbeat.com - 2026-05-09 02:10:08

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 23:31:13

Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates

Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

zacks.com - 2026-05-07 12:16:20

Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%

globenewswire.com - 2026-05-07 07:45:00

Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

zacks.com - 2026-05-04 10:56:10

Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

globenewswire.com - 2026-04-23 08:30:00

Get VCEL Insider Trade Alerts

VCEL Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$56.00

2 analysts

Last Year

$48.80

5 analysts

All Time

$49.00

14 analysts

VCEL Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-05-08 HC Wainwright & Co. Maintain Buy Buy
2026-04-15 Truist Securities Maintain Buy Buy
2026-02-27 HC Wainwright & Co. Maintain Buy Buy
2025-12-18 Truist Securities Maintain Buy Buy
2025-11-10 Truist Securities Maintain Buy Buy
2025-10-15 Truist Securities Maintain Buy Buy
2025-09-17 BTIG Downgrade Buy Neutral
2025-08-01 Canaccord Genuity Maintain Buy Buy
2025-06-16 Stephens & Co. Maintain Overweight Overweight
2025-05-22 Stephens & Co. Maintain Overweight Overweight
2025-04-11 Truist Securities Maintain Buy Buy
2025-03-03 Truist Securities Maintain Buy Buy
2025-02-28 HC Wainwright & Co. Maintain Buy Buy
2025-02-03 Canaccord Genuity Maintain Buy Buy
2025-01-15 Stephens & Co. Maintain Overweight Overweight
2025-01-15 HC Wainwright & Co. Maintain Buy Buy
2024-12-18 Truist Securities Maintain Buy Buy
2024-11-26 BTIG Maintain Buy Buy
2024-11-19 Canaccord Genuity Maintain Buy Buy
2024-11-08 HC Wainwright & Co. Maintain Buy Buy
2024-08-27 TD Cowen Maintain Buy Buy
2024-08-02 HC Wainwright & Co. Maintain Buy Buy
2024-08-02 Stephens & Co. Maintain Overweight Overweight
2024-07-16 Truist Securities Maintain Buy Buy
2024-07-15 BTIG Maintain Buy Buy
2024-05-09 HC Wainwright & Co. Maintain Buy Buy
2024-03-26 Truist Securities Maintain Buy Buy
2024-03-01 HC Wainwright & Co. Maintain Buy Buy
2024-03-01 Truist Securities Maintain Buy Buy
2024-01-25 Truist Securities Upgrade Hold Buy
2024-01-16 HC Wainwright & Co. Maintain Buy Buy
2023-11-09 Truist Securities Maintain Hold Hold
2023-09-21 Truist Securities Maintain Hold Hold
2023-09-21 HC Wainwright & Co. Maintain Buy Buy
2023-09-21 Stephens & Co. Maintain Overweight Overweight
2023-08-08 BTIG Upgrade Neutral Buy
2023-08-03 Truist Securities Maintain Hold Hold
2023-08-03 HC Wainwright & Co. Maintain Buy Buy
2023-07-19 Truist Securities Maintain Hold Hold
2023-05-11 Stephens & Co. Maintain Overweight Overweight
2023-05-11 Truist Securities Maintain Hold Hold
2023-02-27 Truist Securities Maintain Hold Hold
2023-01-31 Truist Securities Maintain Hold Hold
2023-01-27 HC Wainwright & Co. Maintain Buy Buy
2023-01-03 HC Wainwright & Co. Maintain Buy Buy
2022-12-20 Truist Securities Maintain Hold Hold
2022-11-10 HC Wainwright & Co. Maintain Buy Buy
2022-11-10 BTIG Downgrade Buy Neutral
2022-07-18 BTIG Maintain Buy Buy
2022-02-25 SVB Leerink Maintain Outperform Outperform
2021-12-21 Truist Securities Maintain Buy Buy
2021-08-05 SVB Leerink Maintain Outperform Outperform
2021-05-06 HC Wainwright & Co. Maintain Buy Buy
2021-02-25 SVB Leerink Maintain Outperform Outperform
2021-02-25 HC Wainwright & Co. Maintain Buy Buy
2021-01-12 HC Wainwright & Co. Maintain Buy Buy
2021-01-11 Oppenheimer Downgrade Outperform Perform
2020-12-18 Stephens & Co. Maintain Overweight Overweight
2020-10-19 BTIG Maintain Buy Buy
2020-10-15 HC Wainwright & Co. Maintain Buy Buy
2020-10-12 SVB Leerink Maintain Outperform Outperform
2020-09-17 Truist Securities Maintain Buy Buy
2020-04-03 BTIG Maintain Buy Buy
2020-02-03 H.C. Wainwright Maintain Buy Buy
2019-10-09 H.C. Wainwright Maintain Buy Buy
2019-02-28 Needham Downgrade Buy Hold
2019-01-29 Oppenheimer Maintain Outperform Outperform
2018-07-16 Ladenburg Thalmann Upgrade Neutral Buy
2017-06-21 BTIG Research Maintain Buy Buy
2016-04-05 B of A Securities Downgrade Buy Neutral
2016-04-05 Bank of America Downgrade Buy Neutral
2016-03-11 Needham Upgrade Hold Buy